MAGELLAN PHARMACY SOLUTIONS | MAGELLAN MEDICAID ADMINISTRATION

Idaho DUR Quarterly

February 2013 Volume 3, Number 1

Idaho Medicaid Pharmacy Department

1-208-364-1829

Magellan Medicaid Administration Pharmacy Support Center

1-800-922-3987

24 hours/day/7 days per week

- Claims processing assistance
- Drug coverage and payment information
- Eligibility
- Plan limitations
- Coordination of benefits
- Prior authorization status

Idaho Medicaid Pharmacy Call Center

1-866-827-9967

1-208-364-1829

8:00 a.m. – 5:00 p.m. MT

Monday – Friday

Closed federal and state holidays

- Initiate prior authorizations

Prior Authorization Fax

1-800-327-5541

Websites

www.medicaidpharmacy.idaho.gov

- Preferred Drug List
- PA forms
- P&T information

https://Idaho.fhsc.com

Myers and Stauffer LC

Website: http://id.mslc.com

Phone: 1-800-591-1183

Fax: 1-317-571-8481

E-mail: pharmacy@mslc.com

- Establishing and maintaining the Average Actual Acquisition Cost for drugs

DUR Board Meetings

- January 17, 2013
- April 18, 2013
- July 18, 2013
- October 10, 2013

P&T Committee Meetings

- April 19, 2013
- May 10, 2013
- October 11, 2013
- November 15, 2013

Idaho Medicaid Funding and Spending



Original Appropriation for State Fiscal Year (SFY) 2012: General Funds $436.2 million, Total Funds $1.81 billion; 80.8 percent of Health and Welfare funding.

http://www.healthandwelfare.idaho.gov/AboutUs/Publications/tabid/131/Default.aspx

Out of the $1.81 billion in Total Funds appropriated, $141 million (8 percent) was paid out on medications through the outpatient pharmacy program. The money spent on medications is prior to any rebates received from manufacturers. IDHW collected $72 million in rebates during this time. This is included in the receipts area.

Zolpidem High Doses

On January 10, 2013, the Food and Drug Administration (FDA) published a safety announcement regarding the popular insomnia medication zolpidem (trade names Ambien, Ambien CR, Edluar, Zolpimist). The announcement included two important messages:

- The FDA provided new, lower bedtime dosing recommendations for zolpidem.
- The FDA reminded the public about safety concerns including driving impairment or performing other activities requiring alertness the morning after use.

The risk of next-morning impairment is highest for women, who may eliminate the medication more slowly. Impairment is also greater in those taking the extended-release formulation (Ambien CR/zolpidem ER). Manufacturers will be revising the product labeling to reflect the following:

- The NEW immediate release zolpidem dose for women is being lowered from 10 mg to 5 mg.
- The NEW extended release zolpidem dose for women is being lowered from 12.5 mg to 6.25 mg.
- For men, the new labeling will recommend the same lower doses be considered (zolpidem immediate release 5 mg or zolpidem ER 6.25 mg).

A report was run, looking at paid claims between October 1, 2012, and December 31, 2012, to identify the number of Idaho Medicaid recipients who had received zolpidem:

Zolpidem Paid Claims 10/01/2012 – 12/31/2012					
	Male	≥2 per day	Female	≥2 per day	Prescribers
Ambien 5mg	63	10	223	33	209
Ambien 10mg	457		1514		879
Ambien CR 6.25mg	0		0		0
Ambien CR 12.5mg	19		47		44

Based off of these numbers and potential patient safety concerns, the Idaho Medicaid Drug Utilization Review (DUR) Board sent letters to prescribers with a list of their patients (both males and females) who were receiving zolpidem at above the updated recommended doses.

Psychotropic Medication Use in Foster Children

The next red flag in our ongoing review of psychotropic medication use in foster children was looking at those receiving two or more antipsychotics concurrently. The following is a breakdown of the results:

Study Parameters and Results

- Children in Foster Care ages 0–17
- Time Period: 04/01/2012 through 09/30/2012
- 49 patients were identified with fills for two or more different antipsychotics during the time period
  - 26 patients received greater than or equal to 60 days concurrently
  - Other patients received 1–2 fills for a limited time period or sequentially





The next red flag in our on-going series will be looking at recipients on 2 or more medications used in the treatment of ADHD.